Pharmaceutical firms Hikma and Sanofi have participated in a $52m series B round for US-based digital medical treatment developer Click Therapeutics through subsidiaries Hikma Ventures and Sanofi Ventures respectively.
Private equity firm Accelmed co-led the round with asset manager HIG Capital’s HIG BioHealth Partners affiliate. It also featured Health Catalyst Capital, Revelation Partners, K2 HealthVentures, Ridgetop Health and an unnamed biotechnology hedge fund.
Click is developing software to help treat cardiometabolic and autoimmune disorders in addition to psychiatric disorders and chronic pain by helping patients modify their behaviour.
David Benshoof Klein, Clicks co-founder and CEO, said: “Closing our series B is an important milestone for Click that will allow us to further scale our proprietary Click Neurobehavioral Intervention Platform and fund the development of new and innovative digital therapeutics for patients in need.
“We are excited to welcome our new investors and deepen our relationships with existing investors, all of whom share our vision of a new healthcare landscape in which prescription digital therapeutics play a prominent role alongside traditional pharmacological treatments.”
The company had raised an undisclosed amount of seed funding from investors including Supernode Ventures in 2015. Sanofi Ventures led an $18m series A round in 2018 backed by Hikma’s International Ventures and Development subsidiary while K2 HealthVentures and Ridgetop Health were also identified as existing backers.
